Intellia Therapeutics Inc (NASDAQ:NTLA) – Equities researchers at Leerink Swann decreased their Q3 2018 earnings estimates for Intellia Therapeutics in a report released on Wednesday, October 31st. Leerink Swann analyst J. Schwartz now expects that the company will post earnings per share of ($0.53) for the quarter, down from their previous forecast of ($0.15). Leerink Swann also issued estimates for Intellia Therapeutics’ Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.98) EPS, FY2019 earnings at ($2.47) EPS and FY2020 earnings at ($2.83) EPS.
NTLA has been the topic of a number of other reports. Raymond James initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, September 20th. They set a “market perform” rating on the stock. BidaskClub cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. ValuEngine cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Credit Suisse Group initiated coverage on shares of Intellia Therapeutics in a research note on Monday, October 29th. They set a “neutral” rating and a $24.00 price objective on the stock. Finally, Chardan Capital restated a “buy” rating and set a $57.50 price objective on shares of Intellia Therapeutics in a research note on Friday, August 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $35.50.
Shares of NASDAQ NTLA opened at $19.00 on Friday. Intellia Therapeutics has a fifty-two week low of $16.33 and a fifty-two week high of $35.99. The stock has a market cap of $803.21 million, a P/E ratio of -10.11 and a beta of 3.13.
Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Wednesday, October 31st. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The company had revenue of $7.41 million for the quarter, compared to the consensus estimate of $11.58 million. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 1.2% compared to the same quarter last year.
A number of institutional investors have recently modified their holdings of the business. ARK Investment Management LLC raised its position in Intellia Therapeutics by 25.3% in the second quarter. ARK Investment Management LLC now owns 4,513,584 shares of the company’s stock worth $123,492,000 after acquiring an additional 910,608 shares in the last quarter. BlackRock Inc. raised its position in Intellia Therapeutics by 48.4% in the second quarter. BlackRock Inc. now owns 2,556,299 shares of the company’s stock worth $69,940,000 after acquiring an additional 833,337 shares in the last quarter. Morgan Stanley raised its position in Intellia Therapeutics by 17.0% in the second quarter. Morgan Stanley now owns 2,234,299 shares of the company’s stock worth $61,129,000 after acquiring an additional 324,280 shares in the last quarter. Chevy Chase Trust Holdings Inc. raised its position in Intellia Therapeutics by 13.1% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 742,024 shares of the company’s stock worth $21,237,000 after acquiring an additional 86,142 shares in the last quarter. Finally, Federated Investors Inc. PA raised its position in Intellia Therapeutics by 4.5% in the second quarter. Federated Investors Inc. PA now owns 625,300 shares of the company’s stock worth $17,108,000 after acquiring an additional 27,200 shares in the last quarter. Hedge funds and other institutional investors own 66.47% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
See Also: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.